Seaport Therapeutics, Inc. Common Stock Total Liabilities
Seaport Therapeutics, Inc. Common Stock total liabilities. Based on the latest financial reports, Seaport Therapeutics, Inc. Common Stock (SPTX) has total liabilities worth $19.08 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check SPTX financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Seaport Therapeutics, Inc. Common Stock (2024–2025)
Total liabilities of Seaport Therapeutics, Inc. Common Stock from 2024 to 2025. This chart illustrates how Seaport Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Seaport Therapeutics, Inc. Common Stock's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Seaport Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Seaport Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dorian LPG Ltd
NYSE:LPG
|
USA | $713.63 Million |
|
Zhongnanhong Culture Group Co Ltd
SHE:002445
|
China | CN¥540.62 Million |
|
Guangzhou Goaland Energy Conservation Tech Co Ltd
SHE:300499
|
China | CN¥985.08 Million |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥82.76 Million |
|
Growthpoint Properties Australia
AU:GOZ
|
Australia | AU$2.12 Billion |
|
Safety Insurance Group Inc
NASDAQ:SAFT
|
USA | $1.58 Billion |
|
Guangzhou Metro Design And Research
SHE:003013
|
China | CN¥2.93 Billion |
|
Black Diamond Group Limited
TO:BDI
|
Canada | CA$665.69 Million |
Liability Composition Analysis (2024–2025)
This chart breaks down Seaport Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Seaport Therapeutics, Inc. Common Stock asset portfolio.
Liquidity & Leverage Metrics
Seaport Therapeutics, Inc. Common Stock Total Liabilities Ratios Explained
Seaport Therapeutics, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Seaport Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Seaport Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual total liabilities of Seaport Therapeutics, Inc. Common Stock from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $341.55 Million | +0.27% |
| 2024-12-31 | $340.63 Million | -- |
About Seaport Therapeutics, Inc. Common Stock
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-30… Read more